NRX Pharmaceuticals ( (NRXP) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NRx Pharmaceuticals has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the need for additional time to compile necessary information for a complete presentation. The company anticipates filing the report within five calendar days following the original due date. Importantly, NRx Pharmaceuticals does not expect any significant changes in its financial results compared to the corresponding period of the previous fiscal year. The company remains committed to compliance, as indicated by the signature of Michael Abrams, the Chief Financial Officer.
The most recent analyst rating on (NRXP) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.
Spark’s Take on NRXP Stock
According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.
NRX Pharmaceuticals is navigating significant financial hurdles with net losses and negative equity, typical for early-stage biotech firms. However, strategic initiatives and drug development progress provide potential upside. Technical analysis and valuation reflect speculative potential, with the stock currently exhibiting mixed technical signals. The positive outlook from the earnings call highlights strategic moves that could improve the company’s financial health if successful.
To see Spark’s full report on NRXP stock, click here.
More about NRX Pharmaceuticals
Average Trading Volume: 273,969
Technical Sentiment Signal: Sell
Current Market Cap: $46.61M
For detailed information about NRXP stock, go to TipRanks’ Stock Analysis page.